Also known as: Galleri test
A major clinical trial found that Grail's Galleri blood test did not reduce late-stage cancer diagnoses, raising questions about multi-cancer early detection. Meanwhile, the FDA approved a second blood-based colorectal cancer screening test, and an AI-powered liquid biopsy showed promise for Ewing sarcoma.
The NHS-Galleri trial of the Galleri multi-cancer early detection test did not meet its primary endpoint of reducing combined Stage III-IV cancers. Secondary results showed a 26% reduction in Stage IV diagnoses by the third screening round for 12 deadly cancers. The test increased cancer detection rates four-fold compared to standard screening alone.
GRAIL's NHS-Galleri trial missed its primary endpoint of reducing combined Stage III and IV cancer diagnoses. However, the trial showed a 26% reduction in Stage IV diagnoses by the third screening round. Results were presented at ASCO 2026, and GRAIL stock fell following the announcement.
Grail's NHS-Galleri trial of 142,000 participants failed to achieve statistically significant reduction in late-stage cancer diagnoses, though secondary endpoints showed four-fold improvement in overall cancer detection rate. Stock fell 48% following the announcement.
Grail's multi-cancer blood test failed to significantly boost early detection or reduce late-stage diagnoses in a 142,000-person UK trial, raising doubts about regulatory approval and commercial prospects.
